{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T17:00:10Z","timestamp":1789923610702,"version":"4.0.1"},"reference-count":46,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2002,6,12]],"date-time":"2002-06-12T00:00:00Z","timestamp":1023840000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intl Journal of Cancer"],"published-print":{"date-parts":[[2002,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Osteolytic bone metastasis is a frequent problem in the treatment of cancer. Ipriflavone, a synthetic isoflavone that inhibits osteoclastic bone resorption, has been used for the treatment of osteoporosis in some countries. Some other isoflavones also exhibit an antitumor effect <jats:italic>in vitro<\/jats:italic> and <jats:italic>in vivo.<\/jats:italic> Here, we studied the effects of ipriflavone on osteolytic bone metastasis of MDA\u2010231 human breast cancer cells injected intracardially into athymic nude mice (ICR\u2010<jats:italic>nu\/nu<\/jats:italic>). Daily oral administration of ipriflavone at 12 mg\/mouse significantly inhibited the development of new osteolytic bone metastases (<jats:italic>p<\/jats:italic> &lt; 0.05) and the progression of established osteolytic lesions (<jats:italic>p<\/jats:italic> = 0.01), prolonging the life of tumor\u2010bearing mice (<jats:italic>p<\/jats:italic> = 0.01 <jats:italic>vs.<\/jats:italic> control). In addition, ipriflavone reduced the number of osteoclasts at the bone\u2013cancer interface with no severe adverse effects on the host. <jats:italic>In vitro,<\/jats:italic> ipriflavone inhibited the proliferation and DNA synthesis of MDA\u2010231 cells and blocked the ligand\u2010induced phosphorylation of Tyr<jats:sup>845<\/jats:sup> of the EGFR. Ipriflavone did not promote apoptosis of MDA\u2010231 cells. Our results show that ipriflavone not only directly inhibits the growth of cancer cells but also reduces osteoclasts to prevent the soft tissue tumor burden and osteolytic bone metastases. These findings raise the possibility that ipriflavone may be of use as a therapeutic agent against osteolytic bone metastasis. \u00a9 2002 Wiley\u2010Liss, Inc.<\/jats:p>","DOI":"10.1002\/ijc.10517","type":"journal-article","created":{"date-parts":[[2002,9,11]],"date-time":"2002-09-11T02:05:28Z","timestamp":1031709928000},"page":"381-387","source":"Crossref","is-referenced-by-count":16,"title":["Ipriflavone inhibits osteolytic bone metastasis of human breast cancer cells in a nude mouse model"],"prefix":"10.1002","volume":"100","author":[{"given":"Teruo","family":"Iwasaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mutsuko","family":"Mukai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tohru","family":"Tsujimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaharu","family":"Tatsuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Terada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Akedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2002,6,12]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(97)10132-0"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.15.3562"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1210\/endo.140.10.7037"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1210\/er.19.1.18"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.12.3890"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.3.846"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20000615)88:12 <3080::AID-CNCR27>3.0.CO;2-W"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20000615)88:12 <3038::AID-CNCR21>3.0.CO;2-V"},{"key":"e_1_2_6_10_2","first-page":"2602","article-title":"Bisphosphonate treatment inhibits the growth of prostate cancer cells","volume":"61","author":"Lee MV","year":"2001","journal-title":"Cancer Res"},{"key":"e_1_2_6_11_2","first-page":"4418","article-title":"The bisphosphonate ibandronate promotes apoptosis in MDA\u2010MB\u2010231 human breast cancer cells in bone metastases","volume":"61","author":"Hiraga T","year":"2001","journal-title":"Cancer Res"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.5650010207"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01321839"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1006\/bbrc.1994.1318"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02509441"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.5650060913"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.5650090315"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00299315"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(86)90265-1"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(86)90492-3"},{"key":"e_1_2_6_21_2","first-page":"10","article-title":"Ipriflavone: an important bone\u2010building isoflavone","volume":"4","author":"Head KA","year":"1999","journal-title":"Altern Med Rev"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1097\/00042192-199805010-00003"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1159\/000023354"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.285.11.1482"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/0076-6879(91)01032-W"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.3181\/00379727-208-43841"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1202650"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/0022-4731(88)90078-7"},{"key":"e_1_2_6_29_2","first-page":"1049","article-title":"Differentiation of promyelocytic leukemia cells HL\u201060 induced by daidzein in vitro and in vivo","volume":"13","author":"Jing Y","year":"1993","journal-title":"Anticancer Res"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1210\/endo.139.10.6216"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.1997.tb00462.x"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/53.3.661"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002371-200203001-00008"},{"key":"e_1_2_6_34_2","first-page":"4131","article-title":"Inhibition by interleukin 18 of osteolytic bone metastasis by human breast cancer cells","volume":"19","author":"Nakata A","year":"1999","journal-title":"Anticancer Res"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0215(20001120)89:6<488::AID-IJC4>3.0.CO;2-D"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.1609"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0701633"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/0959-8049(94)90186-4"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.274.12.8335"},{"key":"e_1_2_6_40_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20000615)88:12 <2961::AID-CNCR12>3.0.CO;2-L"},{"key":"e_1_2_6_41_2","first-page":"3551","article-title":"Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice","volume":"55","author":"Sasaki A","year":"1995","journal-title":"Cancer Res"},{"key":"e_1_2_6_42_2","doi-asserted-by":"publisher","DOI":"10.1210\/en.137.8.3544"},{"key":"e_1_2_6_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(18)45614-1"},{"key":"e_1_2_6_44_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1010960615370"},{"key":"e_1_2_6_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3835(98)00322-X"},{"key":"e_1_2_6_46_2","doi-asserted-by":"crossref","first-page":"439S","DOI":"10.1093\/ajcn\/70.3.439s","article-title":"Legumes and soybeans: overview of their nutritional profiles and health effects","volume":"70","author":"Messina MJ","year":"1999","journal-title":"Am J Clin Nutr"},{"key":"e_1_2_6_47_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008364402623"}],"container-title":["International Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fijc.10517","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ijc.10517","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T22:17:58Z","timestamp":1697494678000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ijc.10517"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,6,12]]},"references-count":46,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2002,8]]}},"alternative-id":["10.1002\/ijc.10517"],"URL":"https:\/\/doi.org\/10.1002\/ijc.10517","archive":["Portico"],"relation":{},"ISSN":["0020-7136","1097-0215"],"issn-type":[{"value":"0020-7136","type":"print"},{"value":"1097-0215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,6,12]]}}}